Pharma BD Deal Intelligence

Roche Holding AG (via Foundation Medicine, Inc.) / SAGA Diagnostics AB

2026 · Acquisition/Merger · $595M · Pending

Roche's Foundation Medicine subsidiary agreed to acquire Sweden-headquartered (US-RTP-based) SAGA Diagnostics for up to $595M (upfront plus regulatory and commercial milestones) to build out its molecular residual disease (MRD) infrastructure. The transaction is expected to close in Q3 2026.

Key facts

• Announced Apr 18, 2026
• Deal value $595M
• Deal type Acquisition/Merger
• Therapeutic area Oncology MRD monitoring across solid tumors
• Indications Oncology MRD monitoring across solid tumors
• Key assets Pathlight - tumor-informed molecular residual disease (MRD) platform (whole genome sequencing + digital PCR optimized for structural variants); Medicare-covered for early-stage breast cancer recurrence monitoring
• Mechanism Blood-based tumor-informed MRD detection/monitoring (ctDNA)

← Browse all deals  ·  How we score deals